Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial

Cancer Prevention Research

Volumn 8, Issue 10, 2015, Pages 888-894

  Decensi, Andrea ^a,b   Puntoni, Matteo ^a   Guerrieri Gonzaga, Aliana ^c   Cazzaniga, Massimiliano ^c   Serrano, Davide ^c   Lazzeroni, Matteo ^c   Vingiani, Andrea ^c   Gentilini, Oreste ^c   Petrera, Marilena ^a   Viale, Giuseppe ^c,d   Cuzick, Jack ^b   Bonanni, Bernardo ^c   Pruneri, Giancarlo ^c,d  

^a GALLIERA HOSPITAL   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; METFORMIN; PLACEBO; PROGESTERONE RECEPTOR; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BREAST BIOPSY; BREAST HYPERPLASIA; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; AGED; BIOSYNTHESIS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KI-67 ANTIGEN; METFORMIN; MIDDLE AGED; NEOADJUVANT THERAPY;

EID: 84943277146     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0048     Document Type: Article

References (48)

1. Decensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol 2011;29:7-10.
2. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48-60.
3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review andmeta-Analysis of prospective observational studies. Lancet 2008;371:569-78.
4. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2:778-90.
5. Diabetes Prevention Program Research Group. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86.
6. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008;168:2070-80.
7. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al.Metformin and cancer risk in diabetic patients: A systematic reviewand meta-Analysis. Cancer Prev Res 2010;3:1451-61.
8. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, et al. Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-Analysis Taking into Account Biases and Confounders. Cancer Prev Res 2014;7:867-85.
9. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, et al. Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011; 128:783-94.
10. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. J Clin Oncol 2012;30:2593-600.
11. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, et al. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012;135:821-30
12. Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 2014;32:150-7.
13. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, et al. Evaluation of metformin in early breast cancer: Amodification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011;126:215-20.
14. Cazzaniga M, Decensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013;109:2792-97.
15. DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, et al. Differential effects of metformin on breast cancer proliferation according tomarkers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 2014;148:81-90.
16. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC.Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2 breast cancer. Ann Oncol 2012; 23:1771-80.
17. Rivenbark AG, Coleman WB. Field cancerization in mammary carcinogenesis -Implications for prevention and treatment of breast cancer. Exp Mol Pathol 2012;93:391-8.
18. Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-Alpha and Ki-67 expression. Am J Pathol 2002;160:597-604.
19. Santisteban M, Reynolds C, BarrFritcher EG, Frost MH, Vierkant RA, Anderson SS, et al. Ki67: A time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat 2010;121:431-7.
20. Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, et al. Lapatinib activity in premalignant lesions and HER2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res 2011;4:1181-9.
21. Menendez JA, Quirantes-Pine R, Rodrguez-Gallego E, Cuf S, Corominas-Faja B, Cuyas E, et al. Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget 2014;5:2344-8. http://www.agenziafarmaco.gov.it/it/content/recommendations on the use of metformin, 2011
22. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrineresponsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.
23. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656-64.
24. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. International Ki67 in Breast CancerWorking Group of the Breast International Group and North American Breast Cancer Group. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105:1897-906.
25. Decensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, CazzanigaM, Mora S, et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in womenwith ER-positive breast cancer. Ann Oncol 2010;22:582-87.
26. Cuzick J.A Wilcoxon-type test for trend. Stat Med 19854;4:87-90.
27. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
28. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, et al. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 2008;26:806-13.
29. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70.
30. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-88.
31. Zhou CJ, Zhang QH, Zhang TG, Sun SZ, Li H, Wang Y, et al. Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients. Pathol Oncol Res 2009;15:153-8.
32. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, et al. Reduction in Ki-67 in benign breast tissue of high-risk women with the lignin secoisolariciresinol diglycoside. Cancer Prev Res 2010;3:1342-50.
33. Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, et al. Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. Ann Oncol 2014;25:618-23.
34. Von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2012;132:863-70.
35. Liao N, Zhang GC, Liu YH, Li XR, Yao M, Xu FP, et al. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Res Pract 2011;207:1-7.
36. Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18: 1386-9.
37. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 2011;12:496-503.
38. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012 106:1160-65.
39. Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, et al. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. Ann Oncol 2013;24:1859-66.
40. Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, et al. Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer 2013;108:1593-601.
41. Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat 2013;142:415-21.
42. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012;118:4354-62.
43. Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow L, et al. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. J Clin Oncol 33, 2015 (suppl; abstr LBA500).
44. Tannock IF. Effects of food on bioavailability of lapatinib: useful data, wrong conclusion. J Clin Oncol 2009;27:e42;author reply e43.
45. Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, et al. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res 2014;7:199-10.
46. Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-Adjuvant chemotherapy and trastuzumab: An ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann Oncol 2010;21:187-9.
47. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 2013;110:972-7.
48. Iyengar NM, Morris PG, Zhou XK, Gucalp A, Giri D, Harbus MD, et al. Menopause is a Determinant of Breast Adipose Inflammation. Cancer Prev Res. 2015;8:349-58.